ReviewInflammation and regeneration2026
Tissue-resident memory T cells in organ transplantation: implications for immune homeostasis and graft outcomes.
Review in Inflammation and regeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue-resident memory T cells (TRMs) are a non-circulating subset of memory T cells that reside long-term in peripheral tissues. Once considered passive sentinels, TRMs are now recognized as active regulators of transplant immunity. This review summarizes their phenotypic and functional characteristics across key transplanted organs, including kidney, liver, lung, intestine, skin, and heart. Depending on their activation state and microenvironment, TRMs can promote rejection and modulate local immune balance. Advances in single-cell and spatial profiling have revealed TRM heterogeneity, donor-recipient dynamics, and distinct transcriptional programs. We also highlight therapeutic targets such as NKG2D, IL-15, RORγt, and PD-1, and discuss their potential as biomarkers and immunomodulatory tools. Understanding TRMs as both drivers and regulators of alloimmunity offers new strategies for improving transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.